tiprankstipranks
Athira Pharma’s Regulatory Compliance Challenges Threaten Drug Development Pipeline
PremiumCompany AnnouncementsAthira Pharma’s Regulatory Compliance Challenges Threaten Drug Development Pipeline
4M ago
Athira Pharma Reports Q3 2024 Financial Results
Premium
Company Announcements
Athira Pharma Reports Q3 2024 Financial Results
4M ago
Athira Pharma reports Q3 EPS (75c), consensus (71c)
Premium
The Fly
Athira Pharma reports Q3 EPS (75c), consensus (71c)
4M ago
Athira Pharma to focus on ATH-1105 advancement, reduces workforce by 70%
PremiumThe FlyAthira Pharma to focus on ATH-1105 advancement, reduces workforce by 70%
6M ago
Goldman Sachs moves Athira Pharma to Not Rated
Premium
The Fly
Goldman Sachs moves Athira Pharma to Not Rated
6M ago
Athira Pharma downgraded to Neutral from Buy at Rodman & Renshaw
Premium
The Fly
Athira Pharma downgraded to Neutral from Buy at Rodman & Renshaw
6M ago
Athira Pharma trading resumes
PremiumThe FlyAthira Pharma trading resumes
6M ago
Athira  says clinical trial of fosgonimeton for AD primary endpoint not met
Premium
The Fly
Athira says clinical trial of fosgonimeton for AD primary endpoint not met
6M ago
Athira Pharma trading halted, news pending
Premium
The Fly
Athira Pharma trading halted, news pending
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100